drugset / Trial / NCT00050947

Pediatric Epilepsy Study

NCT00050947

Phase 3 Completed 94 enrolled Novartis Pharmaceuticals
Treatment

Summary

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

Timeline

Start
2002-07
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule

Indications